Tumor size was monitored, and the results showed that PINX1 deficient tumors are significantly more sensitive to Talazoparib treatment compared to the PINX1 proficient tumors, suggesting a promising translational possibility (Fig. 2H–J). This evidence concerns the gene PINX1 and neoplasm.